Compare Revolution Medicines Inc. Common Stock (RVMD) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revolution Medicines Inc. Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.41 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is the larger of the two by market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 62 Days on average.
| RVMD | VCIT | |
|---|---|---|
Market Cap | $40.32B | $72.20B |
Volume | 4,855,734 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $221.15 | $84.82 |
52-Week Low | $47.50 | $77.98 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $37.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $78.48, up 0.27% with a bearish technical signal from moving averages. The ETF offers a 4.8% yield and 5.1% yield-to-maturity with a 6-year duration, positioning it as a core fixed-income holding. Recent institutional buying includes Engineers Gate Manager's $1.27 million purchase and HB Wealth Management increasing holdings by 242.9%.
VCIT presents a compelling risk-return profile for income investors seeking corporate bond exposure with low costs. The 0.03% expense ratio provides cost efficiency versus competitors. Risks include interest rate sensitivity and corporate credit quality concerns. Technical indicators suggest near-term consolidation around $78 support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
